sur TRANSGENE (EPA:TNG)
Results of the Transgene General Meeting of May 22, 2026
Transgene held its Combined General Meeting on May 22, 2026, at its headquarters in Illkirch-Graffenstaden. Chaired by Alessandro Riva, the meeting approved all the recommended resolutions, including the financial statements for the 2025 fiscal year and the "Say on Pay" vote. The terms of several directors were renewed, notably those of Sandrine Flory and Benoît Habert, for non-independent positions, as well as those of Emmanuelle Quilès and Carol Stuckley as independent directors.
Two new independent directors have been appointed: Dorothea Ledergerber, with expertise in pharmaceutical production, and Solange Peters, a specialist in oncology. Dorothea Ledergerber brings her experience in the pharmaceutical and biotechnology industry, while Solange Peters, at the CHUV (Lausanne University Hospital), contributes her oncology research.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de TRANSGENE